LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Inicio・Lista de Acciones・Erasca Inc

Erasca Inc

Cerrado

12.81 5.52

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

12.64

Máximo

12.86

Métricas clave
By Trading Economics
Ingresos	-154M -183M
BPA	-0.6
Empleados	103
EBITDA	-5.3M -37M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+66.15% upside

Dividendos
By Dow Jones
Próximas Ganancias	10 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	249M 3.5B
Apertura anterior	7.29
Cierre anterior	12.81

Erasca Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

29 may 2026, 23:08 UTC

Adquisiciones, fusiones, absorciones

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 may 2026, 23:06 UTC

Adquisiciones, fusiones, absorciones

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 may 2026, 20:53 UTC

Ganancias

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 may 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

29 may 2026, 20:33 UTC

Charlas de Mercado

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 may 2026, 20:11 UTC

Ganancias

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 may 2026, 19:47 UTC

Ganancias

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 may 2026, 19:36 UTC

Charlas de Mercado

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 may 2026, 19:34 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

29 may 2026, 19:34 UTC

Charlas de Mercado

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 may 2026, 19:22 UTC

Charlas de Mercado

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 may 2026, 19:05 UTC

Adquisiciones, fusiones, absorciones

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 may 2026, 18:19 UTC

Charlas de Mercado

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 may 2026, 18:12 UTC

Adquisiciones, fusiones, absorciones

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 may 2026, 18:11 UTC

Charlas de Mercado

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 may 2026, 18:10 UTC

Charlas de Mercado

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 may 2026, 17:55 UTC

Ganancias

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 may 2026, 17:55 UTC

Charlas de Mercado

NEAR Protocol Nearly Doubles in May -- Market Talk

29 may 2026, 17:38 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 may 2026, 17:00 UTC

Ganancias

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 may 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

29 may 2026, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

29 may 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

29 may 2026, 16:02 UTC

Charlas de Mercado

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 may 2026, 15:55 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

29 may 2026, 15:55 UTC

Charlas de Mercado

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29 may 2026, 15:50 UTC

Adquisiciones, fusiones, absorciones

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29 may 2026, 15:50 UTC

Adquisiciones, fusiones, absorciones

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29 may 2026, 15:40 UTC

Charlas de Mercado

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29 may 2026, 15:20 UTC

Charlas de Mercado

Canada's Economy Not Looking All That Bright -- Market Talk

Comparación entre iguales

Cambio de precio

Erasca Inc previsión

Precio Objetivo

By TipRanks

66.15% repunte

Estimación a 12 Meses

Media 20.27 USD 66.15%

Máximo 30 USD

Mínimo 9 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Erasca Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Erasca Inc Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.